TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26364041
Drug: Dexketoprofen 10
Normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen 10 mg i.v.
Study: 26364041
Drug: Dexketoprofen 50
Normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen 50 mg i.v.
Study: 11296717
Drug: Various training
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various training procedures in the C‐G Arena
Study: 11296717
Drug: C‐G Arena
Approvals — FDA: no, EMA: no, PMDA: no
Description: C‐G Arena procedures
Study: 8287862
Drug: Sulfadoxine-pyrimethamine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine-pyrimethamine (single curative dose)
Study: 31350236
Drug: Aclidinium bromide
Normalized name: Aclidinium Bromide
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Aclidinium bromide (Acli-BID) administered twice daily for 8 weeks
Study: 31350236
Drug: Tiotropium bromide
Normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiotropium bromide hydrate (Tio-QD) administered once daily for 8 weeks
Study: 24142633
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of pioglitazone daily
Study: 15307518
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy with Allergovit or Novo Helisen Depot for 3 years
Study: 12027048
Drug: Neuroleptic medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptic medications
Study: 8342578
Drug: Intranasal dDAVP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dDAVP (20-40 micrograms according to body weight)
Study: 8342578
Drug: Intravenous dDAVP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dDAVP (2-4 micrograms according to body weight)
Study: 24699555
Drug: Normocaloric group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normocaloric group (100% of daily energy expenditure)
Study: 24699555
Drug: Hypocaloric group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypocaloric group (50% of daily energy expenditure)
Study: 17852143
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens 0.625 mg (CEE, n=24)
Study: 17852143
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens + medroxyprogesterone acetate 5 mg (CEE/MPA, n=34)
Study: 17852143
Drug: 17beta‐estradiol 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17beta‐estradiol 1 mg + norethisterone acetate 0.5 mg (E2/NETA, n=66)
Study: 17852143
Drug: Tibolone 2.5
Normalized name: tibolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 2.5 mg (n=24)
Study: 12145035
Drug: Large-Dose Aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Large-Dose Aprotinin
Study: 7472817
Drug: Placebo tablet,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet, twice daily
Study: 6098051
Drug: icosapentaenoic acid
Normalized name: Icosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: no, EMA: no, PMDA: no
Description: icosapentaenoic acid (20:5n‐3) 150 mg/day for one month
Study: 9788828
Drug: Losartan (L)
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan (L) 50 mg/d
Study: 9770962
Drug: Methotrexate (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (30 mg a week i.v. in hospital, 7-10 mg a week as maintenance)
Study: 3282826
Drug: 2,000 microgram
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2,000 microgram per day dose of beclomethasone dipropionate aerosol (BDP)
Study: 31273505
Drug: Non-intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-intervention group receiving the same CRC education handbook only at discharge preparation
Study: 29357331
Drug: Pulsed fluoroscopy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed fluoroscopy with 8 pulses per second (medium‐dose)
Study: 29357331
Drug: Pulsed fluoroscopy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed fluoroscopy with one pulse per second (low‐dose)
Study: 29357331
Drug: Continuous mode
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous mode fluoroscopy (high‐dose)
Study: 20160654
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 0.05 mg/kg per day
Study: 24569045
Drug: Agomelatine 25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agomelatine 25-50 mg/d
Study: 20496820
Drug: Bilateral injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral injection of 20 units of botulinum toxin into each side of the internal anal sphincter
Study: 20496820
Drug: Posterior injection
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior injection of 25 units of botulinum toxin into the midline posteriorly
Study: 9018513
Drug: Pseudoephedrine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudoephedrine (120 mg)
Study: 10436448
Drug: Low-molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular weight heparin (LMWH) therapy, 40 mg enoxaparin every 12 hours for 7 days, then 40 mg once daily for 3 months
Study: 10436448
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant therapy (coumarin), standard unfractionated heparin followed by coumarin for 3 months
Study: 10436448
Drug: Low-molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular weight heparin (LMWH) therapy
Study: 10436448
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant therapy (coumarin)
Study: 23924679
Drug: 200-mg tablets
Normalized name: pexidartinib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200-mg tablets
Study: 8786960
Drug: 400-mg suspension
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400-mg suspension
Study: 2081489
Drug: nabumetone 1
Normalized name: nabumetone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nabumetone 1 g at night
Study: 2081489
Drug: slow release
Normalized name: Slow Release Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: slow release diclofenac 100 mg at night
Study: 31907645
Drug: QL1101 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: QL1101 (3 mg/kg, intravenously)
Study: 31907645
Drug: Avastin® (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avastin® (3 mg/kg, intravenously)
Study: 28099439
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of all three NSE measurements
Study: 11079282
Drug: Oxandrolone 10
Normalized name: oxandrolone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone 10 mg twice/day for a maximum of 28 days
Study: 7871058
Drug: ritanserin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ritanserin (5 mg) + d-fenfluramine (30 mg)
Study: 24673716
Drug: Low-dose cyclosporine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclosporine with short-term intensified EC-MPS dosing (2160 mg/day to week 6, 1440 mg/day thereafter) and corticosteroids
Study: 24673716
Drug: Low-dose cyclosporine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclosporine with short-term intensified EC-MPS dosing
Study: 24673716
Drug: Standard-dose cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose cyclosporine with standard EC-MPS dosing
Study: 22469884
Drug: Micafungin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin (50 mg/day i.v.)
Study: 22469884
Drug: Itraconazole (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (5 mg/kg/day p.o.)
Study: 18614570
Drug: Intravitreal pegaptanib
Normalized name: pegaptanib
DrugBank: Pegaptanib (DB04895)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravitreal pegaptanib sodium (0.3, 1, and 3 mg)
Study: 16120074
Drug: Ziprasidone 40
Normalized name: ziprasidone 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone 40 mg
Study: 11808825
Drug: Cyclobenzaprine 5
Normalized name: cyclobenzaprine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclobenzaprine 5 mg oral dose
Study: 11808825
Drug: Cyclobenzaprine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclobenzaprine 2.5 to 10 mg tid
Study: 11808825
Drug: Cyclobenzaprine multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclobenzaprine multiple dosing
Study: 2258157
Drug: Endoscopic sclerotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic sclerotherapy (intravariceal and extravariceal injections of Polidocanol)
Study: 23746562
Drug: Phosphatidylserine and
Normalized name: Phosphatidylserine
DrugBank: Phosphatidyl serine (DB00144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphatidylserine and caffeine (400 mg/d PS and 100 mg/d caffeine) for 2 weeks
Study: 19341846
Drug: 10 mcg
Normalized name: D400, 10 mcg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mcg ethinyl estradiol (EE) daily during the hormone-free interval
Study: 19341846
Drug: Placebo during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo during the hormone-free interval
Study: 9118978
Drug: Naloxone (N;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (N; 1.2 mg; 3 ml)
Study: 9118978
Drug: Placebo (P;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (P; 0.9% NaCl saline; 3 ml)
Study: 12516995
Drug: Control (Hepatitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Hepatitis B vaccine)
Study: 3341259
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (50 mg) with Brazil nuts and peanuts
Study: 26796612
Drug: Neostigmine-atropine combination
Normalized name: atropine / neostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine-atropine combination (Group N, n = 45)
Study: 15975103
Drug: Perindopril/indapamide (2.0/0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril/indapamide (2.0/0.625 mg daily, increasing to 4.0/1.25 mg daily after 3 months)
Study: 15975103
Drug: Local standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local standard therapy for glucose control
Study: 14703409
Drug: SBN‐1 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBN‐1 injection at 1 x 10(12)VP
Study: 6992844
Drug: 0.1% halcinonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% halcinonide cream applied once daily
Study: 31541768
Drug: SQ HDM
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ HDM SLIT tablet 10,000 Japanese Allergy Unit
Study: 31309232
Drug: Genistein 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genistein 400 mg/kg
Study: 31309232
Drug: Genistein (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genistein (both doses)
Study: 31309232
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 mg/kg Genistein)
Study: 17972459
Drug: Magnesium (Mg)
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium (Mg)
Study: 17972459
Drug: Correlation between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation between S100beta and Mg
Study: 9440565
Drug: Inhaled formoterol
Normalized name: formoterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled formoterol (FM), 24 microg bid, and placebo tablets (PL)
Study: 9440565
Drug: Inhaled formoterol
Normalized name: formoterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled formoterol (FM), 24 microg bid, and oral prednisolone (PRED), 15 mg daily
Study: 29424248
Drug: Pemetrexed maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed maintenance therapy
Study: 25956613
Drug: Fenofibrate 300
Normalized name: fenofibrate 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 300 mg daily plus pentoxifylline 1200 mg/day in three divided doses for 24 weeks
Study: 22543064
Drug: Volume-controlled ventilation
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Volume-controlled ventilation (VCV) with tidal volume (Vt) of 8 mL•kg(‐1) and PEEP of 0 cm H(2)O
Study: 22543064
Drug: Pressure-controlled ventilation
Normalized name: VENTILATOR FILTER,THERMOFLO #6000S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressure-controlled ventilation (PCV) with tidal volume (Vt) of 8 mL•kg(‐1) and PEEP of 0 cm H(2)O
Study: 16736620
Drug: Three-point relief-tension
Normalized name: Point Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-point relief-tension suspension technique (Group A)
Study: 11083648
Drug: Oxacillin-dicloxacillin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxacillin-dicloxacillin (500 mg orally every 6 h)
Study: 11376633
Drug: Gemfibrozil (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil (900 mg once daily)
Study: 1298571
Drug: Shower-based oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shower-based oral hygiene system (SBOHS)
Study: 2420603
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cisplatin, vinblastine and bleomycin followed by intravenous cyclophosphamide
Study: 2420603
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide (consolidation regimen)
Study: 26679830
Drug: AUD$30 cash
Approvals — FDA: no, EMA: no, PMDA: no
Description: AUD$30 cash following receipt of doses two and three (incentive condition)
Study: 24632109
Drug: family‐based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: family‐based treatment
Study: 19934404
Drug: Selective COX‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective COX‐2 inhibitor
Study: 23338252
Drug: Steroidal anti-inflammatory
Normalized name: Non-steroidal anti-inflammatory agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroidal anti-inflammatory drug
Study: 12419715
Drug: Three minutes
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three minutes of supramaximal stimulation (0.1 Hz, 20 mA) before mivacurium 0.2 mg.kg(‐1)
Study: 12419715
Drug: Ten minutes
Normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ten minutes of supramaximal stimulation (0.1 Hz, 20 mA) before mivacurium 0.2 mg.kg(‐1)
Study: 11153926
Drug: Chelating agent
Normalized name: Chelating agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chelating agent (DMPS)
Study: 4033539
Drug: Prednisone (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (1.2 mg/kg/day for 70 days)
Study: 4033539
Drug: Alkylating agent
Normalized name: Alkylating agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkylating agent alone
Study: 27676085
Drug: Oral extended-release
Normalized name: Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral extended-release calcifediol (30 or 60 µg) once daily at bedtime for 26 weeks
Study: 28685934
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg/d for 6 weeks
Study: 24990161
Drug: Placebo (PL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL) combined with rabeprazole (RPZ) 10 mg/q.d. for 8 weeks
Study: 22883036
Drug: Morphine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine infusion (loading dose 100 µg/kg followed by continuous infusion 10 µg/(kg·h) for 70.05 ± 29.05 h)
Study: 3318543
Drug: Morphine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine infusion
Study: 19001742
Drug: 5% glucose
Normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% glucose infusion (control group)
Study: 12114036
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg simvastatin daily
Study: 10786531
Drug: Education programme
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education programme on how to use and take care of a PIV; details on dosage and duration not available.
Study: 10786531
Drug: Current routines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current routines followed by nurses in the control group; details on dosage and duration not available.
Study: 1972313
Drug: Aldactazine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldactazine alone (altizide + spironolactone, 2 tablets per day)
Study: 1972313
Drug: Aldactazine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldactazine plus a conventional antihypertensive agent (1 or 2 tablets per day)
Study: 31865815
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injection (control)
Study: 25517202
Drug: Caffeine chewing
Normalized name: caffeine Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine chewing gum (3-4 mg · kg(‐1))
Study: 10922420
Drug: Omeprazole (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (80 mg bolus intravenous injection followed by 8 mg per hour infusion for 72 hours, then 20 mg orally per day for 8 weeks)
Study: 10922420
Drug: Placebo (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (same treatment protocol as omeprazole but without the active drug)
Study: 9314091
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg daily for 7 days
Study: 9314091
Drug: Propafenone 300
Normalized name: propafenone 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone 300 mg per os twice a day
Study: 7870968
Drug: Intravenous meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous meperidine (0.25 mg/kg)
Study: 7870968
Drug: Intravenous meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous meperidine (0.5 mg/kg)
Study: 7870968
Drug: Intravenous meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous meperidine (1.0 mg/kg)
Study: 31992589
Drug: Cabozantinib (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib (60 mg once daily)
Study: 20065174
Drug: Preoperative CRT
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative CRT with capecitabine, oxaliplatin, and concurrent radiation followed by surgery and four cycles of postoperative adjuvant capecitabine and oxaliplatin (CAPOX)
Study: 6263072
Drug: Oat-bran diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat-bran diet (100 g of oat bran)
Study: 29605574
Drug: Cinnamon supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamon supplementation (500 mg capsules twice daily for 3 months)
Study: 29605574
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 mg capsules twice daily for 3 months)
Study: 12616104
Drug: IL-2 +
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-2 + GM-CSF (125 mcg/m)
Study: 12616104
Drug: IL-2 +
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-2 + GM-CSF (250 mcg/m)
Study: 10795791
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (4 x 5 g creatine + 1 g glucose x d(‐1), N = 11)
Study: 10795791
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 x 6 g glucose x d(‐1), N = 12)
Study: 8677576
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 400 mg fleroxacin
Study: 8677576
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous (IV) dose of 400 mg fleroxacin
Study: 8677576
Drug: Extended regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended regimen of initial 400 mg IV dose followed by oral therapy (400 mg/day or 200 mg/day for specific patients)
Study: 8677576
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antibiotic prophylaxis mentioned)
Study: 2497545
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg ASA
Study: 195201
Drug: 0.3 g
Normalized name: sorbitol 0.3 GM Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g butylbiguanide and 1.5 g clofibrate/day
Study: 30768860
Drug: Filgotinib maleate
Normalized name: filgotinib maleate
DrugBank: Filgotinib (DB14845)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Filgotinib maleate tablets (100 mg and 200 mg)
Study: 30768860
Drug: Filgotinib maleate
Normalized name: filgotinib maleate
DrugBank: Filgotinib (DB14845)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Filgotinib maleate tablets with food (high-fat meal)
Study: 30768860
Drug: Filgotinib maleate
Normalized name: filgotinib maleate
DrugBank: Filgotinib (DB14845)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Filgotinib maleate tablets with omeprazole
Study: 30768860
Drug: Filgotinib maleate
Normalized name: filgotinib maleate
DrugBank: Filgotinib (DB14845)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Filgotinib maleate tablets with famotidine
Study: 30768860
Drug: Reference tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference tablet (filgotinib hydrochloride)
Study: 28712478
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia (EMLA cream)
Study: 21368587
Drug: Pregabalin 450
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 450 mg
Study: 12798785
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg NaCl
Study: 12798785
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg NaCl
Study: 12798785
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg NaCl
Study: 19234720
Drug: Detection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of antibodies against BCL-2 in patients' sera
Study: 19234720
Drug: Anti-BCL-2 antibodies
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-BCL-2 antibodies
Study: 18184536
Drug: Meracilina/Pen‐Ve‐Oral 500,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meracilina/Pen‐Ve‐Oral 500,000 UI